Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 11—November 2018
Dispatch

Detection and Characterization of Human Pegivirus 2, Vietnam

Nguyen To Anh, Nguyen Thi Thu Hong, Le Nguyen Truc Nhu, Tran Tan Thanh, Catherine Anscombe, Le Ngoc Chau, Tran Thi Thanh Thanh, Chuen-Yen Lau, Direk Limmathurotsakul, Nguyen Van Vinh Chau, H. Rogier van Doorn, Xutao Deng, Motiur Rahman, Eric Delwart, Thuy Le, Guy Thwaites, Le Van TanComments to Author , and for the Southeast Asia Infectious Disease Clinical Research Network
Author affiliations: Oxford University, Ho Chi Minh City, Vietnam (N.T. Anh, N.T.T. Hong, L.N.T. Nhu, T.T. Thanh, C. Anscombe, L.N. Chau, T.T.T. Thanh, H.R. van Doorn, M. Rahman, T. Le, G. Thwaites, L.V. Tan); University of Oxford, Oxford, UK (C. Anscombe, D. Limmathurotsakul, H.R. van Doorn, G. Thwaites); National Institutes of Health, Bethesda, Maryland, USA (C.-Y. Lau); Mahidol Oxford Tropical Research Unit, Bangkok, Thailand (D. Limmathurotsakul); Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam (N.V.V. Chau); Blood Systems Research Institute, San Francisco, California, USA (X. Deng, E. Delwart); University of California, San Francisco (X. Deng, E. Delwart)

Main Article

Table 2

Demographic and clinical features of 6 men with human pegivirus infection, Vietnam*

Pt no. Pt age, y Time point, mo HCV RNA+ HPgV-2 RNA+ Total bilirubin, µmol/L Direct bilirubin, µmol/L AST, UI/L ALT, UI/L CD4 count, cells/µL HIV RNA,
× 103 copies/µL AFP, mg/mL FibroScan result, kPa Symptoms
1
 29
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
2 47 0 Y Y 9.8 0.7 30 24 331 120 1.7 11.8
6 Y Y 4.7 1.6 81 83 518 0.07 2.3 NA
12 Y Y 6.9 3.4 55 61 364 0.04 2.6 11.8 Hepatitis
18
 Y
 Y
 4.8
 2.8
 37
 40
 428
 UND
 2.14
 6.1
 Hepatomegaly
3 32 0 Y Y 4.7 3.4 39 10 288 0.198 0.999 6.5
6 Y Y 12.8 4.7 50 19 510 0.04 1.68 NA
12 Y Y 9.5 5.3 63 25 622 UND 1.88 6.2 Liver fibrosis, hepatomegaly
18
 Y
 Y
 7.6
 3.8
 42
 23
 622
 UND
 1.53
 7.2
 Hepatitis
4 35 0 Y Y 7.8 4.9 67 55 290 61.1 2.96 6.4
6 Y Y 10.7 6.3 77 80 411 UND 3.1 NA
12 Y Y 8.8 3.9 76 72 337 UND 4 8.5 Homogeneous hepatomegaly
18
 Y
 Y
 13
 6.3
 108
 129
 455
 UND
 4.1
 8.1
 Splenomegaly, liver fibrosis
5 34 0 Y Y 4.3 2.8 33 43 291 70.2 3.67 6.1
6 N Y 6.5 2.1 35 43 287 UND 3.83 NA
12 N N 5.4 2.6 33 40 484 UND 4.48 4.5
18
 N
 N
 6.6
 2.6
 73
 85
 546
 UND
 3.9
 3
6 31 0 Y Y 4.5 2.4 52.2 36.5 295 96.8 12.7 22.8
6 Y Y 17.1 12.9 64 62 579 UND 16.74 NA
12 Y N 12.3 4.3 114 121 711 UND 46.3 26.3 Mild liver fibrosis, mild splenomegaly
18 Y N 10.6 4.9 82 89 816 UND 61.01 NA Hepatomegaly, splenomegaly

*Age is patient’s age at diagnosis; time point is the month at which follow-up visit was conducted; 0 was the baseline examination. ALT, alanine aminotransferase; AS, aspartate aminotransferase; NA, not available; Pt, patient; UND, undetectable.
†Patient 1 belongs to the community-acquired infection cohort.

Main Article

1Members of the Southeast Asia Infectious Disease Clinical Research Network are listed at the end of this article.

Page created: October 17, 2018
Page updated: October 17, 2018
Page reviewed: October 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external